By Bachem AG
To get in touch with Bachem AG, simply fill out the form below.
Subscribe to Supplier
Bachem bringing advanced development and manufacturing offers to DDF 2022, Berlin
Bubendorf, Switzerland: –Peptide and Oligonucleotide technology specialist Bachem AG will be prominent at the upcoming 13TH Global Drug Delivery & Formulation Summit, DDF 2022, in Berlin.
Bachem will again be a commercial sponsor of the event in late June and will be represented by a strong team to participate in networking activities.
Advanced development and manufacturing
The Bachem Team headed by Business Development Manager Federica Deco and Sales Manager for Generics, Nicola Zucchetto, will be present under the Bachem logo in the event’s Networking Zone to explore partnership opportunities and answer visitor queries on the company’s advanced peptide and oligonucleotide development and cGMP manufacturing capabilities.
Bachem will also have a branded page in the event catalog, along with a company profile and landing page on the DDF virtual platform, presenting the company’s extensive portfolio of offerings in generic APIs, NCE peptides and oligomers.
“Peptides and oligonucleotides are playing an increasing role in effective drug delivery and therapeutic innovation that transforms lives,” commented Federica Deco.
“As a leading partner in ‘tides, we are pleased to be present at this important conference,” she added.
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides.
With over 50 years of experience and expertise Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.
Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.
For further information, see www.bachem.com.
About DDF 2022
The Drug Delivery & Formulation (DDF) Summit brings together delegates from pharmaceutical, technology and academic fields to discuss latest trends in pharma.
The 13th Summit, DDF 2022, will focus on small molecules and biologics, new technologies, concepts and case studies in areas such as formulation design for poorly soluble compounds, nanotechnology for better deliverability, the latest controlled release technologies, harnessing data for improved patient compliance and the latest smart device technology.
Rescheduled from March, DDF ‘22 is a three-day event opening June 27 at the Maritim proArte Hotel, on Berlin’s Friedrichstrasse. Keynote speakers will include Dr. Andreas Bernkop-Schnürch, Head of the Department Center for Chemistry and Biomedicine at Innsbruck University, who is a leading researcher in drug delivery, nanotechnology and biomaterials.
The event is organized by Mark Allen Group with more information at: www.ddfevent.com